Definition

A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.